What are some of the benefits of the newly approved Lerochol drug over traditional PCSK9 inhibitors for the treatment of familial hyperlipidemia?
Lerodalcibep was approved this past December and uses a different mechanism to inhibit PCSK9. Its potential advantages include once monthly dosing and stability at room temperature for 3 months. It appears to have similar efficacy to the PCSK9 monoclonal antibody therapies lowering LDL 55-60%. Disad...
While there are no CV outcome studies yet with lerodalcibep, a 3rd generation PCSK9 inhibitor, the clinical data shows impressive LDL-reducing efficacy.
The advantages are practical ones:
- monthly injection
- stability at room temperature
- smaller volume of injection.
Based on the beneficial CV outcom...
Lerochol is a small molecule/fusion protein designed to inhibit PCSK9 called lerodalcibep-liga. It will become available in spring/summer 2026. It results in LDL-C reduction of 50-60% so similar efficacy to the monoclonal antibodies. It has been studied in heterozygous familial hypercholesterolemia ...